Rama Elena, May Jan-Niklas, Rix Anne, Lammers Twan, Kiessling Fabian
Institute for Experimental Molecular Imaging, RWTH Aachen University, Germany.
Institute for Experimental Molecular Imaging, RWTH Aachen University, Germany.
Biochem Biophys Res Commun. 2025 Sep 8;778:152346. doi: 10.1016/j.bbrc.2025.152346. Epub 2025 Jul 14.
Immature and hyperpermeable vessels and active transport through endothelial cells, combined with impaired lymphatic clearance and uptake by tumor-associated macrophages, contribute to the accumulation of anticancer drugs in tumors. These so-called "Enhanced Permeability and Retention" (EPR) and "Active Transport and Retention" (ATR) effects are pronounced for nanomedicines. However, while little is known about ATR, EPR is heterogeneous within tumors and patients, limiting the therapeutic efficacy of EPR-based drug delivery systems (DDS). This review discusses strategies to refine and complement EPR-based drug delivery. One possibility is to better stratify patients for therapy using histological and omics biomarkers as well as via companion diagnostics and theranostics. Active targeting of DDS could be used to improve retention and internalization by tumor cells. In addition, active targeting of endothelial cells is increasingly being discussed to promote drug accumulation in tumors by transcytosis. Other strategies include pharmacological or (image-guided) physical priming of the tumor microenvironment. Pharmacological priming has been successfully demonstrated with angiogenic factors to increase vascular maturity, erythropoietin to increase perfusion, and corticosteroids to remodel vessels and the associated extracellular matrix (ECM). Physical priming has been carried out using heat, radiation and ultrasound. The latter is often used in combination with microbubbles that oscillate or burst upon stimulation, mechanically untightening the vessel walls and adjacent ECM. Clinically, this strategy is being evaluated in particular for brain tumors. Thus, EPR-dependent drugs may greatly benefit from patient pre-selection strategies and complementary interventions targeting biological barriers between the injection site and the target.
不成熟且具有高通透性的血管以及通过内皮细胞的主动转运,再加上肿瘤相关巨噬细胞的淋巴清除和摄取功能受损,共同导致抗癌药物在肿瘤中蓄积。这些所谓的“增强渗透与滞留”(EPR)和“主动转运与滞留”(ATR)效应在纳米药物中表现明显。然而,虽然对ATR了解甚少,但EPR在肿瘤内部以及患者之间存在异质性,这限制了基于EPR的药物递送系统(DDS)的治疗效果。本综述讨论了优化和补充基于EPR的药物递送的策略。一种可能性是利用组织学和组学生物标志物以及通过伴随诊断和治疗诊断更好地对患者进行治疗分层。DDS的主动靶向可用于提高肿瘤细胞的滞留和内化。此外,越来越多地讨论对内皮细胞进行主动靶向,以通过转胞吞作用促进药物在肿瘤中的蓄积。其他策略包括对肿瘤微环境进行药理学或(图像引导的)物理预处理。药理学预处理已成功通过血管生成因子增加血管成熟度、促红细胞生成素增加灌注以及皮质类固醇重塑血管和相关细胞外基质(ECM)得到证实。物理预处理已通过热、辐射和超声进行。后者通常与微泡联合使用,微泡在刺激下振荡或破裂,机械性地松开血管壁和相邻的ECM。在临床上尤其针对脑肿瘤对该策略进行评估。因此,依赖EPR的药物可能会从患者预选择策略以及针对注射部位与靶标之间生物屏障的补充干预措施中大大受益。